2021 EHRA实践指南：非维生素K拮抗剂口服抗凝药物在房颤患者中的应用

2021-04-25 欧洲心律学会 Europace (2021) ,1–65.25 April 2021

2021年4月，欧洲心律学会(EHRA)发布了非维生素拮抗剂口服抗凝药物在房颤患者中的应用指南。非维生素拮抗剂口服抗凝药物(NOACs)是房颤患者预防卒中的首选抗凝剂。本文主要针对NOACs在房颤患者

中文标题：

英文标题：

2021 European Heart RhythmAssociation Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

发布机构：

欧洲心律学会

发布日期：

2021-04-25

简要介绍：

2021年4月，欧洲心律学会(EHRA)发布了非维生素拮抗剂口服抗凝药物在房颤患者中的应用指南。非维生素拮抗剂口服抗凝药物(NOACs)是房颤患者预防卒中的首选抗凝剂。本文主要针对NOACs在房颤患者中应用的16种场景提出了实用指导。

点击查看最新解读：

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=46a061c00209956e, title=2021 EHRA实践指南：非维生素K拮抗剂口服抗凝药物在房颤患者中的应用, enTitle=2021 European Heart RhythmAssociation Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation, guiderFrom=Europace (2021) ,1–65.25 April 2021, authorId=0, author=, summary=2021年4月，欧洲心律学会(EHRA)发布了非维生素拮抗剂口服抗凝药物在房颤患者中的应用指南。非维生素拮抗剂口服抗凝药物(NOACs)是房颤患者预防卒中的首选抗凝剂。本文主要针对NOACs在房颤患者, cover=https://img.medsci.cn/2021517/1621242416414_2020535.jpg, journalId=0, articlesId=null, associationId=206, associationName=欧洲心律学会, associationIntro=欧洲心律学会（EHRAE,uropean Heart Rhythm Association)是欧洲心脏病学会的分支，致力于心律失常的预防与管理，以减少心律失常对患者的影响,减少心源性猝死。官方杂志《欧洲心律失常杂志》影响因子为1.839, copyright=0, guiderPublishedTime=Sun Apr 25 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年4月，欧洲心律学会(EHRA)发布了非维生素拮抗剂口服抗凝药物在房颤患者中的应用指南。非维生素拮抗剂口服抗凝药物(NOACs)是房颤患者预防卒中的首选抗凝剂。本文主要针对NOACs在房颤患者中应用的16种场景提出了实用指导。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">点击查看最新解读：</div>, tagList=[TagDto(tagId=364, tagName=房颤), TagDto(tagId=8827, tagName=抗凝药物)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=364, guiderKeyword=房颤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4236, appHits=288, showAppHits=0, pcHits=1235, showPcHits=3948, likes=3, shares=34, comments=10, approvalStatus=1, publishedTime=Mon May 17 18:35:34 CST 2021, publishedTimeString=2021-04-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Mon May 17 17:07:01 CST 2021, updatedBy=6459136, updatedName=艺玮, updatedTime=Fri Jan 05 08:33:25 CST 2024, courseDetails=[], otherVersionGuiders=[OtherVersionToolGuiderDto(projectId=1, id=7a42c1c002e5250d, title=《2021年心房颤动患者非维生素K拮抗剂口服抗凝药物应用实践指南》解读, enTitle=, guiderPublishedTime=Fri Sep 30 00:00:00 CST 2022, createdTime=Tue Oct 25 22:30:07 CST 2022), OtherVersionToolGuiderDto(projectId=1, id=8764d1c002282afb, title=2021 EHRA实践指南《非维生素K拮抗剂口服抗凝药物在房颤患者中的应用指南》更新解读, enTitle=, guiderPublishedTime=Wed Dec 01 00:00:00 CST 2021, createdTime=Fri Dec 03 17:03:57 CST 2021), OtherVersionToolGuiderDto(projectId=1, id=445b61c0015e2325, title=2018 EHRA实践指导：房颤患者应用非维生素K拮抗剂口服抗凝药, enTitle=The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, guiderPublishedTime=Tue Mar 20 00:00:00 CST 2018, createdTime=Tue Mar 27 21:23:22 CST 2018), OtherVersionToolGuiderDto(projectId=1, id=bf8961c001232a5c, title=2016 EHRA实用指南：应用非维生素K拮抗剂类口服抗凝剂治疗非瓣膜性房颤患者（更新）, enTitle=Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary, guiderPublishedTime=Thu Jun 09 00:00:00 CST 2016, createdTime=Mon Jul 11 09:24:51 CST 2016), OtherVersionToolGuiderDto(projectId=1, id=574b61c0012292a2, title=2015 EHRA实用指南：应用非维生素K拮抗剂类口服抗凝剂治疗非瓣膜性房颤患者（更新）, enTitle=Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation., guiderPublishedTime=Mon Aug 31 08:00:00 CST 2015, createdTime=Mon Aug 31 00:00:00 CST 2015)], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 EHRA实践指南：非维生素拮抗剂口服抗凝药物在房颤患者中的应用.pdf)])

2021 EHRA实践指南：非维生素拮抗剂口服抗凝药物在房颤患者中的应用.pdf

下载请点击：

其他版本

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1069354, encodeId=1f6c10693544b, content=非常不错的文章，好好学习，谢谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b8952053819, createdName=1361ec615fm, createdTime=Thu Nov 11 20:07:23 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061849, encodeId=e422106184943, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e185639477, createdName=ms7000000948438358, createdTime=Tue Oct 19 15:23:36 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057490, encodeId=a9dc105e49047, content=不错谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:01:17 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010656, encodeId=433f101065611, content=非维生素拮抗剂口服抗凝药物(NOACs)是房颤患者预防卒中的首选抗凝剂，主要的代表药是哪些？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq9Kq8OPa3fz4aUJTibcNtIicYgrMYtibZ3MymkB8ubpgACUQYL0fYLSEqX3srtp4qicFyZH8m3LpnlAA/132, createdBy=77ef2147274, createdName=CHUXUQIAN, createdTime=Mon Aug 23 16:52:27 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009822, encodeId=af441009822c2, content=学习了，正是我需要的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37515579911, createdName=ms1000001982939558, createdTime=Fri Aug 20 21:06:35 CST 2021, time=2021-08-20, status=1, ipAttribution=)]
2021-11-11 1361ec615fm

非常不错的文章，好好学习，谢谢分享。

116 0
[GetPortalCommentsPageByObjectIdResponse(id=1069354, encodeId=1f6c10693544b, content=非常不错的文章，好好学习，谢谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b8952053819, createdName=1361ec615fm, createdTime=Thu Nov 11 20:07:23 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061849, encodeId=e422106184943, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e185639477, createdName=ms7000000948438358, createdTime=Tue Oct 19 15:23:36 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057490, encodeId=a9dc105e49047, content=不错谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:01:17 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010656, encodeId=433f101065611, content=非维生素拮抗剂口服抗凝药物(NOACs)是房颤患者预防卒中的首选抗凝剂，主要的代表药是哪些？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq9Kq8OPa3fz4aUJTibcNtIicYgrMYtibZ3MymkB8ubpgACUQYL0fYLSEqX3srtp4qicFyZH8m3LpnlAA/132, createdBy=77ef2147274, createdName=CHUXUQIAN, createdTime=Mon Aug 23 16:52:27 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009822, encodeId=af441009822c2, content=学习了，正是我需要的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37515579911, createdName=ms1000001982939558, createdTime=Fri Aug 20 21:06:35 CST 2021, time=2021-08-20, status=1, ipAttribution=)]
2021-10-19 ms7000000948438358

学习一下

122 0
[GetPortalCommentsPageByObjectIdResponse(id=1069354, encodeId=1f6c10693544b, content=非常不错的文章，好好学习，谢谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b8952053819, createdName=1361ec615fm, createdTime=Thu Nov 11 20:07:23 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061849, encodeId=e422106184943, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e185639477, createdName=ms7000000948438358, createdTime=Tue Oct 19 15:23:36 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057490, encodeId=a9dc105e49047, content=不错谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:01:17 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010656, encodeId=433f101065611, content=非维生素拮抗剂口服抗凝药物(NOACs)是房颤患者预防卒中的首选抗凝剂，主要的代表药是哪些？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq9Kq8OPa3fz4aUJTibcNtIicYgrMYtibZ3MymkB8ubpgACUQYL0fYLSEqX3srtp4qicFyZH8m3LpnlAA/132, createdBy=77ef2147274, createdName=CHUXUQIAN, createdTime=Mon Aug 23 16:52:27 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009822, encodeId=af441009822c2, content=学习了，正是我需要的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37515579911, createdName=ms1000001982939558, createdTime=Fri Aug 20 21:06:35 CST 2021, time=2021-08-20, status=1, ipAttribution=)]
2021-10-04 H8888888

不错谢谢分享

112 0
[GetPortalCommentsPageByObjectIdResponse(id=1069354, encodeId=1f6c10693544b, content=非常不错的文章，好好学习，谢谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b8952053819, createdName=1361ec615fm, createdTime=Thu Nov 11 20:07:23 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061849, encodeId=e422106184943, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e185639477, createdName=ms7000000948438358, createdTime=Tue Oct 19 15:23:36 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057490, encodeId=a9dc105e49047, content=不错谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:01:17 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010656, encodeId=433f101065611, content=非维生素拮抗剂口服抗凝药物(NOACs)是房颤患者预防卒中的首选抗凝剂，主要的代表药是哪些？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq9Kq8OPa3fz4aUJTibcNtIicYgrMYtibZ3MymkB8ubpgACUQYL0fYLSEqX3srtp4qicFyZH8m3LpnlAA/132, createdBy=77ef2147274, createdName=CHUXUQIAN, createdTime=Mon Aug 23 16:52:27 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009822, encodeId=af441009822c2, content=学习了，正是我需要的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37515579911, createdName=ms1000001982939558, createdTime=Fri Aug 20 21:06:35 CST 2021, time=2021-08-20, status=1, ipAttribution=)]
2021-08-23 CHUXUQIAN

非维生素拮抗剂口服抗凝药物(NOACs)是房颤患者预防卒中的首选抗凝剂，主要的代表药是哪些？

119 0
[GetPortalCommentsPageByObjectIdResponse(id=1069354, encodeId=1f6c10693544b, content=非常不错的文章，好好学习，谢谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b8952053819, createdName=1361ec615fm, createdTime=Thu Nov 11 20:07:23 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061849, encodeId=e422106184943, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e185639477, createdName=ms7000000948438358, createdTime=Tue Oct 19 15:23:36 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057490, encodeId=a9dc105e49047, content=不错谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:01:17 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010656, encodeId=433f101065611, content=非维生素拮抗剂口服抗凝药物(NOACs)是房颤患者预防卒中的首选抗凝剂，主要的代表药是哪些？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq9Kq8OPa3fz4aUJTibcNtIicYgrMYtibZ3MymkB8ubpgACUQYL0fYLSEqX3srtp4qicFyZH8m3LpnlAA/132, createdBy=77ef2147274, createdName=CHUXUQIAN, createdTime=Mon Aug 23 16:52:27 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009822, encodeId=af441009822c2, content=学习了，正是我需要的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37515579911, createdName=ms1000001982939558, createdTime=Fri Aug 20 21:06:35 CST 2021, time=2021-08-20, status=1, ipAttribution=)]
2021-08-20 ms1000001982939558

学习了，正是我需要的

124 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

2021 EHRA实践指南：非维生素K拮抗剂口服抗凝药物在房颤患者中的应用

《2021年心房颤动患者非维生素K拮抗剂口服抗凝药物应用实践指南》解读

2021 EHRA实践指南《非维生素K拮抗剂口服抗凝药物在房颤患者中的应用指南》更新解读

2018 EHRA实践指导：房颤患者应用非维生素K拮抗剂口服抗凝药

2016 EHRA实用指南：应用非维生素K拮抗剂类口服抗凝剂治疗非瓣膜性房颤患者（更新）

2015 EHRA实用指南：应用非维生素K拮抗剂类口服抗凝剂治疗非瓣膜性房颤患者（更新）

相关指南

拓展阅读

科室

工具

服务